Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Glioma × trebananib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 7 Neoplasms 6 Fallopian Tube Neoplasms 6 Neoplasm Metastasis 5 Carcinoma 4 Colorectal Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Sarcoma 2 Hemangiosarcoma 2 Glioblastoma 2 Gastrointestinal Neoplasms 2 Brain Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Endometrial Stromal 1 Renal Insufficiency 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pathologic Complete Response 1 Oligodendroglioma 1 Melanoma 1 Leukemia, Myelomonocytic, Acute 1 Leukemia, Myeloid, Acute 1 Leukemia, Monocytic, Acute 1 Leukemia, Megakaryoblastic, Acute 1 Leukemia, Erythroblastic, Acute 1 Kidney Neoplasms 1 Kidney Diseases 1

Interventions

Temozolomide 143 Bevacizumab 63 Radiotherapy 60 Magnetic Resonance Spectroscopy 58 Irinotecan 27 Carboplatin 23 Surgical Procedures, Operative 22 Radiation 19 Carmustine 18 Aminolevulinic Acid 18 Specimen Handling 17 Nivolumab 16 Blood Specimen Collection 16 Lomustine 15 Biopsy 15 pembrolizumab 13 Radiotherapy, Intensity-Modulated 12 Cyclophosphamide 12 trametinib 11 Topotecan 11 Radiosurgery 11 Erlotinib Hydrochloride 11 fluorodopa F 18 10 X-Rays 10 IL13-PE38 9 Everolimus 9 ribociclib 8 dabrafenib 8 Surveys and Questionnaires 8 Magnetic Resonance Imaging 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01290263 2017-07-02

Amgen 386 for Recurrent Glioblastoma

Dana-Farber Cancer Institute

Phase 1/2 Completed

48 enrolled 13 charts

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡